NMRA Keith Crandell buys $5.0M worth of shares
Oct 30, 2025, 4:38 AM
0.00%
What does NMRA do
Neumora Therapeutics, a clinical-stage biotechnology company based in Watertown, Massachusetts, went public on September 15, 2023, and has a pipeline targeting neuropsychiatric disorders with seven programs. Its lead candidate, navacaprant, is developed for major depressive disorder, along with other candidates for schizophrenia.
Keith Crandell bought 1,915,700 shares of NMRA on 27 October at $2.61 per share, worth a total of $5.0M. They now own 6,046,907 NMRA shares, or a 46% holding increase.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.